A GLP-1 Guide to Metabolic Health: The Plus SideZ Podcast

A GLP-1 Guide to Metabolic Health: The Plus SideZ Podcast

Looking for real information on GLP-1 medications and weight loss? You’re in the right place.

The Plus SideZ Podcast is your go-to space for science-backed conversations about obesity treatment, weight loss, and living with a chronic metabolic disorder. Hosted by Kim Carlos and Kat Carter, we explore GLP-1 medications like Ozempic, Wegovy, Mounjaro, and Zepbound, featuring insights from leading obesity specialists, endocrinologists, and bariatric surgeons. But this podcast is about more than just medication—it’s about navigating the mental, emotional, and physical journey of reclaiming your health.

We combat misinformation with education from top experts, helping you think critically about the latest research, treatment options, and systemic challenges in obesity care. And at the heart of it all are the powerful, vulnerable stories of our brave community members—people sharing their real experiences on GLP-1 medications, breaking stigma, and taking control of their health.

Ranked in the top 1% of podcasts globally, The Plus SideZ Podcast has won three awards in just 18 months, including two Anthem Awards for social impact. Featured on Good Morning America, Bloomberg News, and ABC Nightline on Hulu, we’re at the forefront of the conversation on weight loss, obesity care, and the fight to end weight bias.

Join us and be part of a movement that’s changing the way the world understands obesity, health, and metabolic wellness.

Our Linktree

https://linktr.ee/theplussidez

Want to donate?

PayPal
https://www.paypal.com/donate/?hosted_button_id=ZSEE2DRPHDSZN

GoFundMe
https://gofund.me/82c8138e

Shop The Plus SideZ Merch Store
https://the-plus-sidez-podcast.printify.me/products/1

Website
https://theplussidez.com/

The World Has More GLP-1s but Who Can Afford Them? Part 2

This week’s GLP-1 news had us thinking about access. Oral Wegovy launched in Germany, and Hims & Hers expanded its GLP-1 services into Australia. But in the U.S., PepsiCo announced it would cut obesity medication coverage while 600,000 people signed up for the new Medicare GLP-1 Bridge program. That is less than 1% of all Medicare beneficiaries, although we still do not know how many were approved or received medication.

Four years after Mounjaro launched, are GLP-1s becoming easier to find but harder to get covered? It felt like the right time to revisit this Season 4 conversation with Dr. Michael “Mick” Crotty and Belinda Hogan about GLP-1 access, obesity care and weight bias around the world.

In Part 2, we discuss:

• Managing daily life and side effects on GLP-1 medication
• Why weight loss slows and plateaus happen
• How the body’s set point may affect weight
• What GLP-1 maintenance really means
• Balancing continued weight loss with stabilization
• Adjusting treatment for long-term care
• What Ireland could learn from the U.S. rollout of GLP-1 medications

Dr. Crotty is a GP, co-founder and clinical lead of My Best Weight in Ireland. Belinda shares her lived experience navigating GLP-1 side effects, plateaus, maintenance and long-term treatment.

CONNECT WITH OUR GUESTS

Dr. Michael “Mick” Crotty

Belinda Hogan

SOURCES